Reproducibility of Arterial Stiffness Indices (Pulse Wave Velocity and Augmentation Index) Simultaneously Assessed by Automated Pulse Wave Analysis and Their Associated Risk Factors in Essential Hypertensive Patients

Matsui, Yoshio; Kario, Kazuomi; Ishikawa, Joji; Eguchi, Kazuo; Shimada, Kazuyuki

doi:10.1291/hypres.27.851

Cited by 138 publications

(114 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,28,34,37 In our study, patients with high AIx-HR75 were shorter than those with normal AIx-HR75. A negative relationship was observed between height and AIx-HR75.…”

Section: Variablessupporting

confidence: 47%

“…[13][14][15] Pulse wave velocity (PWV) and augmentation index (AIx) are widely used as indicators of arterial stiffness and are beneficial for evaluating arterial distensibility in patients with renal diseases. [16][17][18][19] Among different stiffness parameters, PWV is consistently related to cardiovascular mortality, irrespective of when the measurement is taken. 20 AIx is regarded as a measure of systemic arterial stiffness and is derived from the central and radial pressure waveforms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Factors Related to Pulse Wave Velocity and Augmentation Index in Chronic Hemodialysis Patients

et al. 2011

View full text Add to dashboard Cite

Background: Augmentation index (AIx) and pulse wave velocity (PWV) are early markers of atherosclerotic vascular changes and also have been shown to be predictive of cardiovascular disease and total mortality. The aim of our study was to evaluate the relationship between PWV and AIx-HR75, which is the corrected form of AIx according to a heart rate of 75 beats/min, echocardiographic parameters and biochemical parameters in chronic hemodialysis (HD) patients. Subjects and methods: AIx-HR75 and PWV were measured in 556 HD patients by applanation tonometry using the SphygmoCor device. Results: The mean PWV and AIx-HR75 values of the study group were 10.2 ± 2.4 and 28.4 ± 10.2 m/s. A positive correlation was found between PWV and AIx-HR75 (r = 0.214, p = 0.000). AIx-HR75 correlated with age (r = 0.093, p = 0.028), body surface area (BSA) (r = −0.194, p = 0.000), mean arterial pressure (MAP) (r = 0.335, p = 0.000), pulse pressure (PP) (r = 0.212, p = 0.000), cardiothoracic index (r = 0.155, p = 0.016), and presence of left ventricular hypertrophy (r = 0.152, p = 0.001). PWV correlated with MAP (r = 0.208, p = 0.000), PP (r = 0.098, r = 0.021), left ventricular mass (r = 0.105, p = 0.023), and predialysis sodium level (r = −0.105, p = 0.023). In the multivariate analyses, PWV was associated with MAP (t = 3.78, p = 0.000), presence of diabetes (t = 3.20, p = 0.001), and predialysis sodium level (t = −2.06, p = 0.040), and AIx-HR75 was associated with age (t = 2.48, p = 0.014), female sex (t = 3.98, p = 0.000), BSA (t = −2.15, p = 0.033), and MAP (t = 7.02, p = 0.000). Conclusion: There is a strong association between MAP and arterial stiffness parameters in HD patients. We feel that efficient control of blood pressure could lead to reduced arterial stiffness in HD patients.

show abstract

“…18,28,34,37 In our study, patients with high AIx-HR75 were shorter than those with normal AIx-HR75. A negative relationship was observed between height and AIx-HR75.…”

Section: Variablessupporting

confidence: 47%

Section: Introductionmentioning

confidence: 99%

Factors Related to Pulse Wave Velocity and Augmentation Index in Chronic Hemodialysis Patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Furthermore, no significant difference in baPWV was observed between patients treated and those not treated with a statin. Two recent studies (30,31) also reported finding no significant correlation between PWV and serum total cholesterol. In the present study, although patients treated with a statin showed a marked decrease in mean total cholesterol concentration, as well as a significant decrease in baPWV, no significant difference in baPWV was observed between patients treated and those not treated with a statin.…”

Section: Discussionmentioning

confidence: 92%

Selective Angiotensin Receptor Antagonism with Valsartan Decreases Arterial Stiffness Independently of Blood Pressure Lowering in Hypertensive Patients

Nakamura

Fujii²,

Hoshino³

et al. 2005

Hypertens Res

View full text Add to dashboard Cite

“…13,14 However, it has been pointed out that the pulse wave velocity varies according to the changes of blood pressure and sympathetic activity. 15,16 CAVI was measured in this study, and it is calculated by adjusting pulse wave velocity for blood Combined antihypertensive therapy with olmesartan T Ishimitsu et al pressure based on a stiffness parameter (b). Thus, it is thought to be a more accurate index of arterial stiffness.…”

Section: Combined Antihypertensive Therapy With Olmesartan T Ishimitsmentioning

confidence: 99%

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension

et al. 2009

View full text Add to dashboard Cite

To achieve the target blood pressure recommended by the latest guidelines, multiple antihypertensive drugs are needed in most patients. In this study, the efficacy of treatment using an angiotensin II receptor antagonist (ARB) combined with a calcium channel blocker (CCB) or a diuretic was compared from multiple perspectives in patients with hypertension. Twenty-nine patients with essential hypertension, who had failed to achieve their target blood pressure (o130/85 mm Hg for patients o65 years old and o140/90 mm Hg for those X65 years) when treated with the ARB olmesartan at 20 mg day À1 , were additionally given 8-16 mg day À1 of the CCB azelnidipine or 1-2 mg day À1 of trichlormethiazide (a thiazide diuretic) in a randomized crossover manner for 4 months each. At the end of each combination therapy period, blood and urine samples were collected and arterial stiffness was evaluated by measuring the cardio-ankle pulse wave velocity. Compared with monotherapy, the blood pressure was reduced similarly by adding azelnidipine (À12/À10 mm Hg) or trichlormethiazide (À14/À9 mm Hg). The heart rate was decreased with the CCB by 4 b.p.m. (Po0.05), whereas it was unchanged with the thiazide. Serum K, lipids and blood glucose were not significantly changed with either combination, whereas serum uric acid was increased with the thiazide (Po0.01) but was unchanged with azelnidipine. Plasma levels of renin, angiotensin II and aldosterone were also increased with the thiazide period, whereas high-sensitivity C-reactive protein and oxidized low-density lipoprotein were decreased with azelnidipine. In addition, the cardio-ankle vascular index, a parameter of arterial stiffness, was decreased with the azelnidipine period but was unchanged with the thiazide period (Po0.01). It is suggested that the combination of olmesartan and azelnidipine has advantages over the combination of olmesartan and a thiazide with respect to avoiding hyperuricemia, sympathetic activation, renin-angiotensin-aldosterone system stimulation, inflammation, oxidative stress, and increased arterial stiffness in patients with moderate hypertension. These properties may provide cardiovascular protection in addition to the hypotensive effect.

show abstract

Reproducibility of Arterial Stiffness Indices (Pulse Wave Velocity and Augmentation Index) Simultaneously Assessed by Automated Pulse Wave Analysis and Their Associated Risk Factors in Essential Hypertensive Patients

Cited by 138 publications

References 32 publications

Factors Related to Pulse Wave Velocity and Augmentation Index in Chronic Hemodialysis Patients

Factors Related to Pulse Wave Velocity and Augmentation Index in Chronic Hemodialysis Patients

Selective Angiotensin Receptor Antagonism with Valsartan Decreases Arterial Stiffness Independently of Blood Pressure Lowering in Hypertensive Patients

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension

Contact Info

Product

Resources

About